Selinexor (KPT-330) 1393477-72-9

.cp_wz table {border-top: 1px solid #ccc;border-left:1px solid #ccc; } .cp_wz table td{border-right: 1px solid #ccc; border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;} .cp_wz table th {border-right: 1px solid #ccc;border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;}


Molecular Weight:

443.31 Selinexor (KPT-330) is an orally bioavailable Selective CRM1 Inhibitor. Phase 2.

Biological Activity

As the clinical candidate analog of KPT-185, KPT-330 exhibits similar
effects on the viability of T-ALL cells and elicits rapid apoptotic
response. KPT-330 also reduces cell growth in MOLT-4, Jurkat, HBP-ALL,
KOPTK-1, SKW-3, and DND-41 cell lines, with IC50 values of 34-203 nM.


KPT-330 dramatically suppresses the growth of T-ALL cells (MOLT-4) and
AML cells (MV4–11) in vivo, with little toxicity to normal
haematopoietic cells. In SCID mice with diffuse human MM
bone lesions, KPT-330 inhibits MM-induced bone lysis and prolongs
survival. Moreover, KPT-330 directly impairs osteoclastogenesis and bone
resorption by blocking RANKL-induced NF-κB and NFATc1, with minimal
impact on osteoblasts and BMSCs.

Contact us if you need more details on 1393477-72-9. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Selinexor 1393477-72-9、KPT-330 1393477-72-9. If these products fail to match your need, please contact us and we would like to provide relevant information.

Product Categories : Transmembrane Transporters > CRM1 Inhibitor